Alternative routes for 64Cu production using an 18 MeV medical cyclotron in view of theranostic applications

Dellepiane, Gaia; Casolaro, Pierluigi; Mateu, Isidre; Scampoli, P.; Braccini, S.

doi:10.1016/j.apradiso.2022.110518

Cited by 11 publications

(6 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The thick target yield of 67 Cu and 64 Cu were calculated from Eq. ( 3) on the basis of the cross section measurements reported in this paper and in Dellepiane et al (2022c) and are shown in Fig. 6 as a function of the entry energy.…”

Section: Production Testsmentioning

confidence: 92%

See 1 more Smart Citation

Optimized production of 67Cu based on cross section measurements of 67Cu and 64Cu using an 18 MeV medical cyclotron

Dellepiane

Casolaro

Gottstein

et al. 2023

Applied Radiation and Isotopes

View full text Add to dashboard Cite

Section: Production Testsmentioning

confidence: 92%

“…As for the 67 Zn(p,𝛼) 64 Cu nuclear reaction, its cross section was measured in the framework of our research program on Cu radioisotopes from 89.6% enriched 67 ZnO targets (Dellepiane et al, 2022c) ( 64 Zn: 1.56%; 66 Zn: 3.88%; 67 Zn: 89.60%; 68 Zn: 4.91%; 70 Zn: 0.05%) .…”

Section: Cross Section Measurementsmentioning

confidence: 99%

Optimized production of 67Cu based on cross section measurements of 67Cu and 64Cu using an 18 MeV medical cyclotron

Dellepiane

Casolaro

Gottstein

et al. 2023

Applied Radiation and Isotopes

View full text Add to dashboard Cite

“…Additionally, several alternative routes for 64 Cu production are reported, such as 64 Zn(n,p) 64 Cu [68] and 63 Cu(n,γ) 64 Cu [69]. Recently, Dellepiane et al reported a 64 Cu production via 65 Cu(p,pn) 64 Cu and 67 Zn(p,α) 64 Cu reactions [70].…”

Section: Gamma-emitting Radioisotopesmentioning

confidence: 99%

“…Obtaining a sufficient amount of the 67 Cu isotope with a high specific activity using accelerator-based production has always been a difficult task [75]. The commonly used proton-based reactions 68 Zn(p,2p) 67 Cu and 70 Zn(p,α) 67 Cu are complicated by the co-production of 64 Cu. Recently, 67 Cu production via the 70 Zn(p,α) 67 Cu reaction with a compact cyclotron was reported by Brühlmann et al [76].…”

Section: Gamma-emitting Radioisotopesmentioning

confidence: 99%

“…The commonly used proton-based reactions 68 Zn(p,2p) 67 Cu and 70 Zn(p,α) 67 Cu are complicated by the co-production of 64 Cu. Recently, 67 Cu production via the 70 Zn(p,α) 67 Cu reaction with a compact cyclotron was reported by Brühlmann et al [76]. In addition, deuteron beam irradiation of enriched 70 Zn target 70 Zn(d,αn) 67 Cu is a highly promising method for 67 Cu production [77,78].…”

Section: Gamma-emitting Radioisotopesmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals

Krasnovskaya,

Abramchuck,

Erofeev

et al. 2023

IJMS

View full text Add to dashboard Cite

Copper-64 (T1/2 = 12.7 h) is a positron and beta-emitting isotope, with decay characteristics suitable for both positron emission tomography (PET) imaging and radiotherapy of cancer. Copper-67 (T1/2 = 61.8 h) is a beta and gamma emitter, appropriate for radiotherapy β-energy and with a half-life suitable for single-photon emission computed tomography (SPECT) imaging. The chemical identities of 64Cu and 67Cu isotopes allow for convenient use of the same chelating molecules for sequential PET imaging and radiotherapy. A recent breakthrough in 67Cu production opened previously unavailable opportunities for a reliable source of 67Cu with high specific activity and purity. These new opportunities have reignited interest in the use of copper-containing radiopharmaceuticals for the therapy, diagnosis, and theranostics of various diseases. Herein, we summarize recent (2018–2023) advances in the use of copper-based radiopharmaceuticals for PET, SPECT imaging, radiotherapy, and radioimmunotherapy.

show abstract

A Brief Review of Radiolabelling Nucleic Acid‐Based Molecules for Tracking and Monitoring

Edelmann,

Sladojevich,

Husbands

et al. 2024

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

The rise of nucleic acid‐based therapeutics continues apace. At the same time, the need for radiolabelled oligonucleotides for determination of spatial distribution is increasing. Complex molecular structures with mostly multiple charges and low solubility in organic solvents increase the challenge of integrating radionuclides. In preclinical research, it is important to understand the fate of new drug candidates in biodistribution studies, target binding or biotransformation studies. Depending on a specific question, the selection of a respective radiolabelling strategy is crucial. Radiometals for molecular imaging with positron emission tomography or single‐photon computed tomography generally require an attached chelating agent for stable complexation of the metal with the oligonucleotide, whereas labelling using carbon‐11/‐14 or tritium allows incorporation of the radioisotope into the native structure without altering it. Moreover, the suitability of direct radiolabelling of the oligonucleotide of interest or indirect radiolabelling, for example, by a two‐step pretargeting approach, for the study design requires consideration. This review focuses on the challenges of radiolabelling nucleic acid‐based molecules with beta‐plus, gamma and beta‐minus emitters and their use for tracking and monitoring.

show abstract

Alternative routes for 64Cu production using an 18 MeV medical cyclotron in view of theranostic applications

Cited by 11 publications

References 45 publications

Optimized production of 67Cu based on cross section measurements of 67Cu and 64Cu using an 18 MeV medical cyclotron

Optimized production of 67Cu based on cross section measurements of 67Cu and 64Cu using an 18 MeV medical cyclotron

Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals

A Brief Review of Radiolabelling Nucleic Acid‐Based Molecules for Tracking and Monitoring

Contact Info

Product

Resources

About